RxDoctor Payments Data

Brian Keuer, MD

Urology · Lake Barrington, ILNPI 1184812471

Payments from drug & device makers

$8,815in general payments, 2019–2025

Across 197 payments — averaging $44.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Neotract Inc.$2K
  • Dendreon Pharmaceuticals LLC$750
  • Astellas Pharma US Inc$400
  • AbbVie$391
  • Sumitomo Pharma America, Inc.$331
  • plus $3K from 31 others

What the payments were for

  • Consulting fees$1,88021%
  • Travel & lodging$1,31915%
  • Food & beverage$5,61764%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,815 in reported general payments places this provider in the 75th percentile of 550 urology providers in Illinois.

See all urology providers in Illinois

Medicare billing

Part B allowed, 2024
$745,911
Medicare patients
1,295
Services billed
24,048

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix359$917,497
XtandiEnzalutamide58$866,679
MyrbetriqMirabegron155$116,204
GemtesaVibegron54$40,556
Mirabegron ErMirabegron19$11,241
Tamsulosin Hcl731$9,728
Dutasteride191$6,430
Potassium Citrate ErPotassium Citrate52$5,301
Finasteride343$4,950
Silodosin34$2,890
Alfuzosin Hcl ErAlfuzosin Hcl88$2,117
Solifenacin Succinate48$1,755
Testosterone19$1,323
Tadalafil14$699
Oxybutynin Chloride ErOxybutynin Chloride29$578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$400$982,883213 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$331$958,053413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 550 urology providers in Illinois.

Other urology in Lake Barrington

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →